Review ArticleReview
Targeting PP2A for cancer therapeutic modulation
Halle Ronk, Jared S. Rosenblum, Timothy Kung and Zhengping Zhuang
Cancer Biology & Medicine October 2022, 19 (10) 1428-1439; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0330
Halle Ronk
1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Jared S. Rosenblum
1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Timothy Kung
1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Zhengping Zhuang
1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
References
- 1.↵
- Kinch MS.
- 2.↵
- 3.↵
- 4.↵
- 5.↵
- Ruediger R,
- Van Wart Hood JE,
- Walter G.
- 6.
- 7.
- 8.↵
- McCright B,
- Virshup DM.
- 9.↵
- Janssens V,
- Goris J,
- Van Hoof C.
- 10.↵
- Guo F,
- Stanevich V,
- Wlodarchak N,
- Sengupta R,
- Jiang L,
- Satyshur KA, et al.
- 11.↵
- D’Arcy BM,
- Swingle MR,
- Papke CM,
- Abney KA,
- Bouska ES,
- Prakash A, et al.
- 12.↵
- Chen X,
- Lu S,
- Zhang Y.
- 13.↵
- Pan M,
- Cao J,
- Fan Y.
- 14.↵
- Wang G.
- 15.↵
- Tu GG,
- Zhan JF,
- Lv QL,
- Wang JQ,
- Kuang BH,
- Li SH.
- 16.↵National Library of Medicine (U.S.). A phase Ib open-label study of LB-100 in combination with carboplatin/etoposide/atezolizumab in untreated extensive-stage small cell lung carcinoma. Identifier NCT04560972. 2021, May. https://clinicaltrials.gov/ct2/show/NCT04560972.
- 17.National Library of Medicine (U.S.). A phase 1b/2 study evaluating the safety and efficacy of intravenous LB-100 in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) who had disease progression or are intolerant to prior therapy. Identifier NCT03886662. 2019, April. https://clinicaltrials.gov/ct2/show/NCT03886662.
- 18.National Library of Medicine (U.S.). Phase II trial of LB100, a protein phosphatase 2A inhibitor, in recurrent glioblastoma. Identifier NCT03027388. 2019, January. https://clinicaltrials.gov/ct2/show/NCT03027388.
- 19.↵National Library of Medicine (U.S.). Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Identifier NCT1837667. 2013, April-2017, January. https://clinicaltrials.gov/ct2/show/NCT01837667.
- 20.↵
- Bryant JP,
- Levy A,
- Heiss J,
- Banasavadi-Siddegowda YK.
- 21.↵
- Cui J,
- Wang H,
- Medina R,
- Zhang Q,
- Xu C,
- Indig IH, et al.
- 22.↵
- Maggio D,
- Ho WS,
- Breese R,
- Walbridge S,
- Wang H,
- Cui D, et al.
- 23.↵
- Mirzapoiazova T,
- Xiao G,
- Mambetsariev B,
- Nasser MW,
- Miaou E,
- Singhal SS, et al.
- 24.↵
- Uddin MH,
- Pimentel JM,
- Chatterjee M,
- Allen JE,
- Zhuang Z,
- Wu GS.
- 25.↵
- Yen Y,
- Chien M,
- Wu P,
- Ho C,
- Huang KC,
- Chiang S, et al.
- 26.↵
- Zhang C,
- Hong CS,
- Hu X,
- Yang C,
- Wang H,
- Zhu D, et al.
- 27.↵
- Liu L,
- Wang H,
- Cui J,
- Zhang Q,
- Zhang W,
- Xu W, et al.
- 28.↵
- Song Q,
- Wang H,
- Jiang D,
- Xu C,
- Cui J,
- Zhang Q, et al.
- 29.↵
- Hu C,
- Yu M,
- Ren Y,
- Li K,
- Maggio DM,
- Mei C, et al.
- 30.↵
- Lai D,
- Chen M,
- Su J,
- Liu X,
- Rothe K,
- Hu K, et al.
- 31.↵
- Ho WS,
- Sizdahkhani S,
- Hao S,
- Song H,
- Seldomridge A,
- Tandle A, et al.
- 32.↵
- Hao S,
- Song H,
- Zhang W,
- Seldomridge A,
- Jung J,
- Giles AJ, et al.
- 33.↵
- 34.↵
- Stupp R,
- Mason WP,
- van der Bent MJ,
- Weller M,
- Fisher B,
- Taphoorn MJB, et al.
- 35.↵
- Yu MW,
- Quail DF.
- 36.↵
- 37.↵
- 38.
- 39.
- Goldmann J,
- Kwidzinski E,
- Brandt C,
- Mahlo J,
- Richter D,
- Bechmann I.
- 40.↵
- Karmur BS,
- Philteos J,
- Abbasian A,
- Zacharia BE,
- Lipsman N,
- Levin V, et al.
- 41.↵
- Newick K,
- Moon E,
- Albelda SM.
- 42.↵
- 43.↵
- Sun J,
- Zhang D,
- Wu S,
- Xu M,
- Zhou X,
- Lu X, et al.
- 44.↵
- Yang T,
- Kong Z,
- Ma W.
- 45.↵
- 46.↵
- Rudin CM,
- Brambilla E,
- Faivre-Finn C,
- Sage J.
- 47.↵
- Perez EA,
- Moreno-Aspitia A,
- Thompson EA,
- Andorfer CA.
- 48.↵
- 49.↵
- 50.↵
- Xu J,
- Xu Z,
- Zhou J,
- Zhuang Z,
- Wang E,
- Boerner, et al.
- 51.↵
- 52.↵
- Sinicrope FA,
- Mahoney MR,
- Smyrk TC,
- Thibodeau SN,
- Warren RS,
- Bertagnolli MM, et al.
- 53.↵
- Piñol V,
- Castells A,
- Andreu M,
- Castellví-Bel S,
- Alenda C,
- Llor X, et al.
- 54.↵
- Poynter JN,
- Siegmund KD,
- Weisenberger DJ,
- Long TI,
- Thibodeau SN,
- Lindor N, et al.
- 55.↵
- Wert-Carvajal C,
- Sánchez-García R,
- Macías JR,
- Sanz-Pamplona R,
- Pérez AM,
- Alemany R, et al.
- 56.↵National Library of Medicine (U.S.). Study of Induction of PD-1 Blockade in Subjects with Locally Advanced Mismatch Repair Deficient Solid Tumors. Identifier NCT04165772. 2019, November. https://clinicaltrials.gov/ct2/show/NCT04165772.
- 57.↵
- 58.↵
- Misaghi A,
- Goldin A,
- Awad M,
- Kulidjian AA.
- 59.↵
- Bruland OS,
- Høifødt H,
- Saeter G,
- Smeland S,
- Fodstad O.
- 60.↵
- Bai X,
- Zhi X,
- Zhang Q,
- Liang F,
- Chen W,
- Liang C, et al.
- 61.↵
- Rosenblum JS,
- Pant H.
- 62.↵
- Chen J,
- Kwong DL,
- Cao T,
- Hu Q,
- Zang L,
- Ming X, et al.
- 63.↵
- 64.↵
- Kamath K,
- Wilson L,
- Cabral F,
- Jordan MA.
- 65.↵
- 66.↵
- 67.↵
- 68.↵
- Jamieson CHM,
- Ailles LE,
- Dylla SJ,
- Muijtjens M,
- Jones C,
- Zehnder JL, et al.
- 69.↵
- Okano A,
- Miyawaki S,
- Hongo H,
- Dofuku S,
- Teranishi Y,
- Mitsui J, et al.
- 70.↵
- 71.↵
- Walcott BP,
- Nahed BV,
- Mohyeldin A,
- Coumans JV,
- Kahle KT,
- Ferreira MJ.
- 72.↵
- Krause DS,
- Van Etten RA.
- 73.↵
- 74.↵
- 75.↵
- Hoffman A,
- Taleski G,
- Sontag E.
- 76.↵
- 77.↵
- Chung V,
- Mansfield AS,
- Braiteh F,
- Richards D,
- Durivage H,
- Ungerleider RS, et al.
In this issue
Targeting PP2A for cancer therapeutic modulation
Halle Ronk, Jared S. Rosenblum, Timothy Kung, Zhengping Zhuang
Cancer Biology & Medicine Oct 2022, 19 (10) 1428-1439; DOI: 10.20892/j.issn.2095-3941.2022.0330
Jump to section
Related Articles
- No related articles found.